Comparison of the Pharmacokinetics （PK）and Pharmacodynamics （PD）Biosimilarity of Insulin Aspart Injections After Single-Dose Subcutaneous Administration to Healthy Volunteers

The present study is designed to compare the pharmacokinetic, pharmacodynamic and safety characteristics of UBLIN® (test product) and NovoRapid® (reference product) in healthy male participants. The treatment consists of one single dose of the test or reference product, administered during each of the two study periods, separated by 7 days between dosing. A total of 44 participants will be enrolled in this trial and randomized in a 1:1 ratio into two groups (A/B), stratified by race (Asian, non-Asian).

NCT Number	NCT07600944
Lead Sponsor	Zhuhai United Laboratories Co., Ltd.
Conditions	Pharmacokinetics and Pharmacodynamics
Enrollment	44 participants
Start Date	2026-05-06
Primary Completion	2026-06-13 (estimated)
Study Completion	2026-07-03 (estimated)
Updated on ClinicalTrials.gov	2026-08-14